Covid-19 Oct 07

Rich world could be close to normal by late 2021 if vaccine works: Gates

Gates' Foundation is talking to pharma companies to ramp up manufacturing of a Covid-19 vaccine; ones developed by leading western groups may get regulatory approval first, as none of the Phase-3 trials in Russia and China have a highly regarded regulator

by Guy Faulconbridge and Kate Holton
Rich world could be close to normal by late 2021 if vaccine works: Gates
Bill Gates, co-chair of the Bill & Melinda Gates Foundation; attends a panel discussion during the IMF/World Bank spring meeting in Washington in April 2018. File photo by Yuri Gripas/ Reuters.

Rich countries could be back to close to normal by late 2021 if a Covid-19 vaccine works, is ready soon and distributed properly at scale, Microsoft founder Bill Gates said on Tuesday.

"By late next year you can have things going back pretty close to normal – that's the best case," Gates, 64, told The Wall Street Journal CEO Council.

"We still don't know whether these vaccines will succeed," Gates said. "Now the capacity will take time to ramp up. And so the allocation within the US, and between the US and other countries will be a very top point of contention."

Covid-19 vaccines developed by Pfizer/BioNTech and AstraZeneca/Oxford University are two of the leading candidates in the race to be first to get regulatory approval in the West.

The head of the World Health Organisation said on Tuesday that a vaccine against Covid-19 may be ready by the end of the year.

Gates, who made a fortune from Microsoft, has since given $36 billion to the Bill & Melinda Gates Foundation, which aims to tackle extreme poverty and poor healthcare.

Last month the foundation signed an agreement with 16 pharmaceutical companies, which Gates said committed them to scaling up manufacturing at an unprecedented speed, and making sure that approved vaccines reach broad distribution as early as possible.

VACCINE RACE

Russia has pushed ahead with its Covid-19 vaccine with mass public vaccinations alongside the main human trial, raising concerns among some observers that it was prioritising national prestige over solid science and safety.

"We're also talking with Russia and China," Gates said. "None of their vaccines are in a Phase III trial with a highly regarded regulator overseeing that trial."

Gates said that from a scientific point of view the Russian and Chinese vaccines were perfectly valid projects but the absence of a well-respected Phase III study could limit their attractiveness outside their respective countries.

"The Western companies are further ahead on doing these Phase III studies and so if those come out well and they're offered at low cost, I doubt there'll be a lot of Russian or Chinese vaccines going outside of those countries," he said.

Gates added that in the United States people should be thinking about ways to reduce hesitancy about having a Covid-19 vaccine when one is ready.

"You know, here in the US, we should already be thinking about which voices will help reduce the hesitancy. And so we can get a level of vaccination that really has a chance of stopping (it)."

Asked who did best at balancing the competing health and economic needs, Gates said: "South Korea, Australia – because this is an exponential event, a little bit of intelligence early on makes a huge difference," he said.

(Additional reporting by Paul Sandle; Editing by Giles Elgood)